On May 31, 2025, Arvinas, Inc. along with Pfizer announced positive Phase 3 trial results for their breast cancer treatment vepdegestrant, showing a 43% reduction in disease progression for patients with specific mutations. The study also revealed a median progression-free survival of 5.0 months versus 2.1 months with standard treatment, with findings presented at the ASCO conference and published in the New England Journal of Medicine.